Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab plus chemotherapy versus placebo plus chemotherapy in unresectable locally advanced pancreatic cancer
MOH_2020-01-29_008669Phase 3Completed
- Sponsor
- FibroGen
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Pamrevlumab + chemotherapy with Placebo + chemotherapy (2 arms). Started Dec 2019; status: completed.
02
Drugs
pamrevlumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on MOH_2020-01-29_008669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-29_008669.